reason report
product oper jacqui ross vice-president investor
relat number investor meet came away
view continu drive growth
beyond even diversifi driver growth rang
larg popul sequenc studi oncolog
liquid biopsi consum genom market continu
inflect toward broader adopt believ signific
room grow next sever year beyond recent
announc acquisit remain highli complementari
long read short read combo deliv power
valu proposit oncolog rare diseas diagnost
rais revenu pt
assess next leg growth benefit util larger
popul studi catalyz million genom
genom variou popul sequenc project
announc far run believ
key stakehold includ fund agenc labs/institut need
see benefit util data popul scale move
forward million sampl accord reduct
sequenc price per gb gigabas unlik catalyz growth
near term custom path volume-bas
discount decid run sampl
reason drove time acquisit key use
case pacb diagnost outlin key reason
time acquisit includ expect
releas zmw chip standard optim librari prep
improv accuraci benefit chip
iter believ deliv signific benefit
oncolog rare diseas two key market compani
help identifi refractori variant structur variat
manag remain upbeat overal opportun oncolog
consum genom manag remain confid
continu growth oncolog tissu liquid biopsi
lab custom continu demand larger panel size deeper
consum genom market still earli signific room
grow market highli under-penetrated market
opportun consum genom test like ancestri
drive strong adopt even broader popul
emerg market albeit lower price point believ
consum array technolog benefit popul even
open significantli larger market opportun
life scienc tool diagnost
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
creat bluematrix
compani inform leerink partner llc research
revenu mm ep exclud charg amort intang
pleas refer page import disclosur price chart analyst certif
remain outperform rais price target
believ custom compet race reduc sequenc cost
continu manifest novaseq nextseq order consum pull-through
broader uptak across ilmn sequenc line-up believ sequenc market
continu expand dramat number sampl depth coverag novaseq
continu drive signific reduct sequenc cost hiseq
 lead edg line sight reach genom long-term
beyond high throughput platform also continu drive double-digit growth desktop
system includ nextseq essenti key high growth market includ non-invas
pre-nat test nipt oncolog tissu liquid biopsi routin genet test
hospit test provid continu domin sequenc market world-wide
address market size well life scienc genet test reproduct
health oncolog consum genom market share revenu
market share sequenc unit believ ilmn market share accuraci throughput
enterpris level servic product factor continu keep custom bound
despit custom consid higher price recent announc
acquisit expect close believ
complementari long read technolog addit short read sequenc synthesi sb
technolog believ continu domin next-gen sequenc keep
drive sequenc cost lower lead elast demand sampl deeper
manag meet highlight number diversifi growth driver
beyond complementari ilmn-pacb acquisit see growth
recent host omead ostadan evp product oper jacqui ross
vice-president investor relat number investor meet came away view
continu drive growth beyond even diversifi driver
growth rang larg popul sequenc studi oncolog liquid biopsi
consum genom market continu inflect toward broader adopt believ
signific room grow next sever year
evp ostadan insight complementari natur ilmn pacb long read short read
ls sr help assess rational deal path forward
look promis could accomplish sb sequenc
synthesi short read sequenc
enjoy much diversifi posit today across high growth end-market set stage
anoth year strong growth base manag feedback clear us
today much diversifi vs prior year broad end-market exposur
rang popul sequenc oncolog tissu liquid biopsi
grow consum genom market believ oncolog repres market
consum genom reach market world-wide long-term includ emerg
market posit today contrast year ago though agre
market wouldnt develop without launch new product address wide
custom base across key end-market manag believ diversif provid
resili overal market posit give view like
deliv anoth year strong growth despit track deliv top-lin growth
recal novaseq launch earli signific instrument
upgrad histori deliv top-lin growth track deliv
top-lin growth year
assess next leg growth would take catalyz million
lead genom center institut genom factori novogen mcrogen etc today
access price gener data larg popul
sequenc project project includ uk depart social care
biobank genom european effort includ franc grow list genom nih
us research program potenti sequenc genom annual long-term
see genom project major growth driver come year
novaseq deliv genom per year averag believ novaseq would
requir gener data genom annual
catalyz genom manag believ key stakehold includ
govern fund agenc labs/institut gener data need see benefit
util sever thousand genom popul scale studi alreadi
underway uk genom england project near complet genom
believ larg research consortium research group fund agenc current analyz
pilot project move forward increasingli larger genom number popul
studi also statist power call benefit thu studi design remain
essenti long-term success project result believ price/gb
reduct per genom potenti less half
requir drive next leg pop seq project util benefit pilot
project genom clear believ stakehold like proceed
new product innov need yet volume-bas discount
continu drive elast demand
believ tier price structur aka volume-bas discount continu
provid requisit discount price per gb need potenti reach
custom will drive enough volum still new product innov
like requir get genom appear line
expect medacorp convers larger custom access discount via
long-term contract outlin lower price/gb return larger volum recent
convers medacorp specialist highlight discount list price return
annual consum revenu novaseq believ price tier
must transpar order custom realiz equal benefit respect size
need expect new innov potenti new flow cell beyond could
requir catalyz genom price
manag remain upbeat overal opportun oncolog liquid
manag remain confid continu growth oncolog tissu
liquid biopsi lab custom continu demand larger panel size deeper
sequenc compar earlier day sequenc cost major concern lead
restrict panel size panel omni guardant gene
panel demand gene panel clear custom would like continu
expand panel size perform deeper sequenc drive consum demand even higher
continu see growth across oncolog liquid biopsi project requir
sequenc gener close revenu clinic market alreadi evp
ostadan appear excit next leg growth oncolog broadli increasingli
compani come tabl test rang late stage therapi manag
consum genom highli under-penetrated still emerg market
amazon cite ancestri dna product one best seller black friday-
cyber monday weekend highlight continu growth consum genom
manag believ consum genom market still earli signific room
grow market highli under-penetrated given market popul
opportun consum genom test like ancestri
drive strong adopt even broader popul emerg market albeit lower price
point believ consum array technolog benefit popul even
open significantli larger market opportun
consum genom product reli microarray product servic account
sale grow y/i recal dtc sampl
genotyp platform volum previou year combin despit
earli inning consum genom revolut believ market still come
speed season learn consum behavior on-line tool need
drive higher sale growth could bump along road market learn
consum behavior import note consum genom remain highli
under-penetrated less half ilmn array consum revenu line
gener
also import note array instrument revenu number mostli consum
genom compani make sens given increment growth buyer long-stand
product gener array instrument revenu massiv
uptick uptick appear driven larg custom
point earlier specul custom gear box
holiday season array servic revenu also mostli consum genom
compani given array instrument uptim essenti
highli complementari acquisit ilmn short read long
read combo present power valu proposit diagnost
announc market close nov acquir
consensu revenu believ acquisit highli complementari plug
import gap portfolio expand overal market opportun ad
long read remov competit overhang oxford nanopor bgi
technolog acquisit open door new market realiz yet long read
technolog follow path elast demand price per gb gigabas reduct
combin data remain unexplor far transact cash expect
close
acquisit plug long-stand technolog gap long read though
major sequenc market center around short read sr technolog
fast econom long read lr technolog cater refractory/repeat
genom region variant seen structur genom applic believ
pacb current genom cost per gb vs genom vs
gap narrow introduct zmw zero-mod
waveguid would deliv genom price point potenti
competit
three reason drove time acquisit
though believ key reason acquisit time immin launch
zmw chip number key factor play role time acquisit
manag point major workflow chang upcom would
make much easier perform sampl prep instrument make
line standard librari prep special one thu potenti open door
effici workflow up-front sequenc believ librari prep
potenti autom deliv prepar librari sr lr workflow
enhanc believ appreci custom gener use
eas use instrument
expect accuraci improv iter zmw
chip well size chip continu shrink enhanc signal nois
expect smaller well one molecul like enter space
well like expand provid even better signal nois
remain confid deliv technolog price point drive
volum higher workflow deliv see path deliv
data higher accuraci lower price point long-term
use case ilmn-pacb diagnost highlight potenti market
believ certain use case -pacb lr sr combin
like highli complementari benefici help structur variant
refractori sb chemistri chemistri believ benefit rare
undiagnos diseas rugd oncolog previous unexplor variant
identifi lend power two complementari technolog rugd oncolog two
largest market -pacb combo deliv signific benefit
long-term undetect variant clinic util given limit softwar
develop effort behind data enough effort place build
tool drive util data even broadli resourc tool
expect util lr combin lr sr shine
manag howev point data-intens natur technolog
movi captur chip requir faster comput even
petabyt storag take step address challeng evidenc recent
acquisit edico dragen platform informat side hold potenti
build api custom use set-up plug directli aw cloud platform
thu make much easier custom answer individu question experi
queri still think elast demand remain central ilmn thesi believ
continu play reduct cost sequenc cost/gb drive market expans
omead ostadan evp product oper
omead ostadan execut vice presid product oper evp
ostadan come two decad experienc sequenc market respons
central product develop well global oper qualiti assum role
senior vice presid product develop role expand includ
compani global oper qualiti function mr ostadan join
solexa vice presid market help build compani market organ
prior work appli biosystem variou capac year mr
ostadan earn biochemistri univers california davi
wharton school univers pennsylvania
share current trade price-to-earnings consensu ep averag
life scienc tool lst group multipl note view potenti
unbound market opportun major popul develop develop
world touch sequenc form test next year use
dcf analysi beta long-term growth rate wacc arriv
price target believ remain strong forc sequenc market
see revenu growth continu outer year addit believ long-
term growth rate conserv estim given sequenc repres somewhat
unbound market opportun view still applic continu
explor beyond current one
margin profil would face downward pressur given new entrant innov competitor
understand domin market share genom sequenc industri
tmo ion torrent main competit believ major
competit near term product instal expens
competitor given near-monopoli howev custom balk price major
innov develop futur expect gross oper margin
declin given competit note occupi market share industri
instal base due expens equip instal highlight
import price consum elast product
affect reimburs decis medicar although posit cash
flow critic mass instal base demand genom test product
affect reimburs rate declin reimburs like lead lower demand
product activ turn would affect usag consum product
seen effect reimburs rate chang peer genom test industri
drop-off would certainli impact revenu believ ilmn growth profil could
significantli slow reimburs rate lower would like contribut
regul fda could major impact revenu well current
sell diagnost product laboratori consid laboratori develop test
ldt fda yet regul ldt due prolifer product industri
fda may revers cours regul ldt addit product requir fda
approv intend use diagnosi diseas expand
product purpos subject greater test complianc standard
increas oper expens believ addit regul ilmn ldt
research-us product would result risk estim
high level capit expenditur involv oper mean disrupt capital-expenditure
spend could lead slower growth level capital-expenditure need launch support new
product import growth slight delay instrument shipment
consum could caus guidanc miss miss guidanc close
one less hiseqx system anticip given small room error
one deal leverag capital-expenditure maintain oper risk
servic
good sold
interest expens incom
add net incom attribut non-control interest
net incom attribut
sg sale
 sale
oper expens sale
sg revenu
 revenu
compani report leerink partner estim
